Quick Answer
Sagimet Biosciences Inc. reported Research And Development Expense of $39.05 million for the year ending 2025.
- Sagimet Biosciences Inc. showed an increase of +1.6% in Research And Development Expense from 2024 to 2025.
- This data is from Sagimet Biosciences Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $6.37 million | Q3 2022: $6.84 million | Q1 2023: $4.49 million | Q2 2023: $4.68 million | Q3 2023: $4.96 million | Q1 2024: $5.26 million | Q2 2024: $6.31 million | Q3 2024: $12.65 million | Q1 2025: $15.34 million | Q2 2025: $7.25 million | Q3 2025: $9.73 million.
- Over the full 4 years of available data (2022 to 2025), Sagimet Biosciences Inc.'s Research And Development Expense has grown by 56.7%.
- Historical annual values: Fiscal year 2025: $39.05 million | Fiscal year 2024: $38.44 million | Fiscal year 2023: $19.78 million | Fiscal year 2022: $24.92 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: